AUS
NZ
UK
CA
USA
IND
Highlights
● Neurotech International (ASX:NTI) partners with RH Farma Dooel Skopje under a binding development agreement.
● The collaboration focuses on a pharmaceutical-grade broad-spectrum cannabinoid drug for pediatric neurological disorders.
● The agreement supports production scale-up in adherence to stringent EU pharmaceutical manufacturing standards.
Neurotech International (ASX:NTI) operates within the biopharmaceutical sector with a dedicated focus on pediatric neurological disorders. This field encompasses innovative approaches to treating conditions such as Autism Spectrum Disorder, Rett Syndrome, and PANDAS/PANS. The recent binding agreement with RH Farma Dooel Skopje, a North Macedonian subsidiary of European Cannabis Company, aligns with efforts to develop pharmaceutical-grade cannabinoid treatments using proprietary CO2 extraction technology.
Strategic Collaboration
The collaboration between Neurotech International (ASX:NTI) and RH Farma Dooel Skopje establishes a framework for advancing the production of a broad-spectrum cannabinoid drug designed for pediatric applications. The agreement involves an upfront payment and additional services scheduled over the next year. This strategic move integrates European Cannabis Company’s manufacturing expertise, ensuring that production complies with EU Good Manufacturing Practice standards. The partnership reinforces the commitment to quality manufacturing and scalable production methods in an international setting.
Clinical Research and Regulatory Compliance
Clinical research initiatives have included rigorous trials across various neurodevelopmental conditions. Completed studies have encompassed phase II/III trials in Autism Spectrum Disorder along with phase I/II trials in PANDAS/PANS and Rett Syndrome. Regulatory clearance has been obtained for further investigations in spastic cerebral palsy. These clinical milestones serve as a foundation for a structured pathway toward regulatory approvals in Australia through provisional registration methods. This approach emphasizes adherence to established pharmaceutical standards and clinical protocols.
Global Expansion and Production Scaling
The strategic alliance with European Cannabis Company strengthens Neurotech International’s (ASX:NTI) global expansion framework. The integration of advanced production techniques with established regulatory compliance measures enhances the capability to scale manufacturing operations. The shared vision among both entities focuses on addressing a significant need within pediatric neurological care, facilitating streamlined entry into international markets while maintaining rigorous quality control.
